Akari Therapeutics (AKTX) Return on Invested Capital (2025 - 2026)

Akari Therapeutics' (AKTX) quarterly Return on Invested Capital came in at 0.01% in Q1 2026, down 102.22% quarter-over-quarter from 0.01% in Q4 2025.

Akari Therapeutics (AKTX) Return on Invested Capital (2025 - 2026) Analysis & Trends

Akari Therapeutics has disclosed Return on Invested Capital across 2 years of filings, most recently posting 0.01% for Q1 2026.

Return on Invested Capital for Q1 2026 came in at 0.01%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed N/A YoY), and the FY2025 annual result was 0.01%, changed N/A from the prior year.
Return on Invested Capital came in at 0.01% for Q1 2026 at Akari Therapeutics, down from 0.01% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.01% in Q4 2025 to a low of 0.05% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.01%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-0.01%
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-0.01%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.00%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	0.00%

Download Data